---
title: "Valneva names Gerd Zettlmeissl board chair, replacing Anne-Marie Graffin"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290855720.md"
description: "Valneva appointed independent director Dr. Gerd Zettlmeissl as board chair, succeeding Anne-Marie Graffin, who will remain vice-chair. Zettlmeissl brings over 40 years of biopharma experience. Additionally, shareholders reappointed CEO Thomas Lingelbach to the board for a three-year term."
datetime: "2026-06-25T15:45:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290855720.md)
  - [en](https://longbridge.com/en/news/290855720.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290855720.md)
generator: "portal-rs"
---

# Valneva names Gerd Zettlmeissl board chair, replacing Anne-Marie Graffin

-   Valneva named independent director Dr. Gerd Zettlmeissl chair of its board at a post-AGM board meeting. \* Zettlmeissl is a vaccine expert and biotech entrepreneur with more than 40 years of biopharma scientific and leadership experience. \* He served as board chair at several non-profit vaccine groups and public and private biotech companies over the past 15 years. \* He succeeds Anne-Marie Graffin, who led the board for three years and will remain vice-chair. \* Shareholders also reappointed CEO Thomas Lingelbach to the board for a three-year term. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valneva SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606251145PRIMZONEFULLFEED1001209631) on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VALN.US](https://longbridge.com/en/quote/VALN.US.md)

## Related News & Research

- [Biopharma firm BioXcel Therapeutics files for bankruptcy in US](https://longbridge.com/en/news/297256243.md)
- [Korro Bio CEO to speak at Citi Biopharma Back to School Summit fireside chat](https://longbridge.com/en/news/297172967.md)
- [Gilead breaks ground on Foster City biologics facility in $32 billion US investment push](https://longbridge.com/en/news/297254548.md)
- [Bank of New York Mellon Corp Invests $62.79 Million in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/297140434.md)
- [Theravance Biopharma reports CYPRESS Phase 3 miss but FDA grants Type C meeting to discuss future trial](https://longbridge.com/en/news/296955575.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**